ZA932491B - Vaccines - Google Patents

Vaccines

Info

Publication number
ZA932491B
ZA932491B ZA932491A ZA932491A ZA932491B ZA 932491 B ZA932491 B ZA 932491B ZA 932491 A ZA932491 A ZA 932491A ZA 932491 A ZA932491 A ZA 932491A ZA 932491 B ZA932491 B ZA 932491B
Authority
ZA
South Africa
Prior art keywords
pct
vesicles
sec
date
date jan
Prior art date
Application number
ZA932491A
Other languages
English (en)
Inventor
James Alexander
James Macdonald Brewer
Original Assignee
Proteur Molecular Design Limit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteur Molecular Design Limit filed Critical Proteur Molecular Design Limit
Publication of ZA932491B publication Critical patent/ZA932491B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA932491A 1992-04-07 1993-04-07 Vaccines ZA932491B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207731A GB9207731D0 (en) 1992-04-07 1992-04-07 Improvements in or relating to vaccines

Publications (1)

Publication Number Publication Date
ZA932491B true ZA932491B (en) 1993-11-02

Family

ID=10713695

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932491A ZA932491B (en) 1992-04-07 1993-04-07 Vaccines

Country Status (16)

Country Link
US (1) US5679355A (de)
EP (1) EP0634937B1 (de)
JP (1) JP2690620B2 (de)
KR (1) KR950700758A (de)
CN (1) CN1085449A (de)
AT (1) ATE158185T1 (de)
AU (1) AU3899793A (de)
CA (1) CA2132547C (de)
DE (1) DE69314020T2 (de)
FI (1) FI944676A0 (de)
GB (1) GB9207731D0 (de)
HU (1) HUT69935A (de)
NO (1) NO943739D0 (de)
NZ (1) NZ251402A (de)
WO (1) WO1993019781A1 (de)
ZA (1) ZA932491B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
EP0734251B1 (de) * 1993-12-17 2009-10-14 Novavax, Inc. Verfahren zur übertragung eines biologisch aktiven materials an eine zelle
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9515868D0 (en) * 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
HUP0101619A3 (en) * 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
FI112825B (fi) * 2001-07-11 2004-01-15 Antti Nissinen Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus
EP1528915A2 (de) * 2002-07-03 2005-05-11 Aphton Corporation Liposomaler impfstoff
CN1711074B (zh) * 2002-11-15 2010-10-06 尼普洛株式会社 脂质体
FR2850872A1 (fr) * 2003-02-12 2004-08-13 Ethypharm Sa Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
BRPI0414021B1 (pt) 2003-08-28 2023-09-26 Becton, Dickinson And Company Dispositivo de injeção intradérmica
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
WO2010014686A1 (en) 2008-07-30 2010-02-04 Aleva Neurotherapeutics, S.A. Apparatus and method for optimized stimulation of a neurological target
EP2783727B1 (de) 2008-11-12 2016-11-09 Ecole Polytechnique Fédérale de Lausanne Mikrohergestellte Neurostimulationsvorrichtung
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011067297A1 (en) 2009-12-01 2011-06-09 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Microfabricated neurostimulation device and methods of making and using the same
EP2552536B1 (de) 2010-04-01 2016-06-08 Ecole Polytechnique Fédérale de Lausanne (EPFL) Vorrichtung zur interaktion mit nervengewebe
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012093706A1 (ja) * 2011-01-07 2012-07-12 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
JP5855583B2 (ja) * 2011-01-07 2016-02-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013111012A2 (en) * 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN110585588A (zh) 2014-05-16 2019-12-20 阿莱瓦神经治疗股份有限公司 可植入式微电极装置
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
EP3411111A1 (de) 2016-02-02 2018-12-12 Aleva Neurotherapeutics SA Behandlung von autoimmunkrankheiten mit tiefhirnstimulation
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2597346B1 (fr) * 1986-04-22 1989-08-18 Oreal Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
AU603659B2 (en) * 1987-03-13 1990-11-22 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
LU87449A1 (fr) * 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
AU654858B2 (en) * 1991-03-28 1994-11-24 Novavax, Inc. Lipid vesicle containing water-in-oil emulsions

Also Published As

Publication number Publication date
EP0634937A1 (de) 1995-01-25
CA2132547C (en) 2000-06-06
AU3899793A (en) 1993-11-08
KR950700758A (ko) 1995-02-20
CN1085449A (zh) 1994-04-20
NO943739L (no) 1994-10-05
HUT69935A (en) 1995-09-28
ATE158185T1 (de) 1997-10-15
JP2690620B2 (ja) 1997-12-10
US5679355A (en) 1997-10-21
CA2132547A1 (en) 1993-10-14
EP0634937B1 (de) 1997-09-17
GB9207731D0 (en) 1992-05-27
FI944676A (fi) 1994-10-06
NZ251402A (en) 1996-10-28
WO1993019781A1 (en) 1993-10-14
HU9402904D0 (en) 1995-01-30
DE69314020T2 (de) 1998-08-06
DE69314020D1 (de) 1997-10-23
JPH07505389A (ja) 1995-06-15
NO943739D0 (no) 1994-10-05
FI944676A0 (fi) 1994-10-06

Similar Documents

Publication Publication Date Title
ZA932491B (en) Vaccines
NO954786D0 (no) Hjelpestoffer for vaksiner mot åndedretts-syncytalvirus
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
DK0760649T3 (da) Præparater af fluticason-propionat
AU2001295673A1 (en) Vaccine composition
IL142948A0 (en) Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
ATE153071T1 (de) Neue proteinhaltige partikeln
AU5457596A (en) Adjuvants for viral vaccines
CA2086094A1 (en) Vaccine compositions containing liposomes
AU5457496A (en) Adjuvants for viral vaccines
AU5646101A (en) Immunotherapeutic methods and compositions
DE69420970T2 (de) Impfstoff zubereitungen
DE69322960T2 (de) Empfängnisverhütender impfstoff
Zhang Study of protective effect of outer membrane proteins of Vibrio cholerae with monoclonal antibodies.